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Genome-wide association analyses of >200,000 individuals identify 58 genetic loci for chronic 
inflammation and highlights pathways that link inflammation and complex disorders 
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Abstract 
C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation that is associated 
with multiple complex diseases. The genetic determinants of chronic inflammation remain largely 
unknown, and the causal role of CRP in several clinical outcomes is debated. We performed two genome-
wide association studies (GWAS), HapMap and 1000Genomes imputed, of circulating CRP levels using 
data from 88 studies comprising 204,402 European individuals. Additionally, we performed in silico 
functional analyses and Mendelian randomization analyses with several clinical outcomes. The GWAS 
meta-analyses of CRP revealed 58 distinct genetic loci (P<5×10-8). After adjustment for body mass index 
in the regression analysis, the associations at all except three loci remained. The lead variants at the 
distinct loci explained up to 7.0% of the variance in circulating CRP levels. We identified 66 gene sets 
that were organized in two substantially correlated clusters, one mainly comprised of immune pathways, 
and the other characterized by metabolic pathways in the liver. Mendelian randomization analyses 
revealed a causal protective effect of CRP on schizophrenia and a risk increasing effect on bipolar 
disorder. Our findings provide further insights in the biology of inflammation that may lead to 
interventions to treat inflammation and its clinical consequences.   
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Introduction 
Inflammation plays a key role in the development of complex diseases such as cardiovascular disease1, 
type 2 diabetes2, Alzheimer’s disease3, and schizophrenia4. C-reactive protein (CRP) is a sensitive marker 
of chronic low-grade inflammation5, and elevated serum levels of CRP have been associated with a wide 
range of diseases6-8. Unraveling the genetics of inflammation may provide further insights into the 
underlying biology of inflammation, and may identify therapeutic targets to attenuate inflammation.  
 The genetic determinants of CRP have only been partly characterized. In 2011, our group 
published a HapMap-based meta-analysis of genome-wide association studies (GWAS) including a 
discovery panel of up to 65,000 individuals and found 18 loci that were associated with CRP levels9. 
Increasing study sample size in GWAS and denser mapping of the genome with further advanced 
imputation panels may help to identify further genes associated with the phenotypes of interest10; 11. 
Furthermore, by using genetic instrumental variables (i.e., a genetic score), Mendelian randomization 
(MR) allows investigation of the potential causal effect of an exposure on clinical outcomes, and may help 
to understand the causal pathways that link the exposure with the outcome12. The causal role of CRP in the 
development of diseases is still controversial13, and the causal pathways that link inflammation to complex 
disorders are only partly understood. 
 We applied two large-scale GWAS on circulatory levels of CRP using HapMap and 
1000Genomes (1KG) imputed data to identify genetic determinants of chronic inflammation. Because 
body mass index (BMI) is a major determinant of CRP levels, we additionally conducted GWAS adjusted 
for BMI to identify associated loci independent of BMI. To identify any sex differences in genetic 
determinants of chronic inflammation, we further conducted GWAS in men and women separately. We 
applied in silico functional analyses on the identified loci to obtain better insights into the biological 
processes potentially regulating chronic inflammation. Finally, we conducted MR analyses to provide an 
improved understanding of the causal relation between CRP and several related clinical outcomes. 
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Material and methods 
GWAS for circulating CRP levels 
We conducted a meta-analysis of GWAS including individuals of European ancestry within the Cohorts 
for Heart and Aging Research in Genomic Epidemiology consortium Inflammation Working Group of the 
(CIWG)14. The CIWG invited cohorts for participation in the HapMap GWAS meta-analysis of CRP 
levels in 2012. In 2014 and in light of our assessment which showed complementary value of HapMap 
and 1KG imputed GWAS10, we invited studies to participate in the 1KG GWAS meta-analysis. The 1KG 
GWAS may help to identify loci that were not covered in the HapMap GWAS and fine map loci found in 
the HapMap GWAS. Cohorts were allowed to participate in either the HapMap or 1KG GWAS, or both. 
Here we present both a HapMap (204,402 individuals from 78 studies) and 1KG (148,164 individuals 
from 49 studies) imputed genotypes GWAS meta-analysis. All participating cohorts implemented a pre-
specified study plan comprising study design, data quality check, data analysis, and data sharing. We 
measured serum CRP in mg/L using standard laboratory techniques (Supplemental Methods), and natural 
log-transformed the values. Individuals with auto-immune diseases, individuals taking immune-
modulating agents (if this information was available), and individuals with CRP levels 4SD or more away 
from the mean were excluded from all analyses. The characteristics of the participants are presented in 
Table S1. We filtered individuals and genetic variants based on study-specific quality control criteria 
(Table S2). At each individual study site, we tested genetic variants for association with CRP levels using 
an additive linear regression model adjusted for age, sex, and population substructure, and accounting for 
relatedness, if relevant. Before meta-analysis, we filtered variants based on imputation quality at R2 index 
of >0.4. To avoid type-I error inflation, we corrected study-specific GWAS for genomic inflation. For the 
HapMap study, we conducted fixed effect meta-analyses for each genetic variant, using the inverse 
variance-weighted method implemented in GWAMA15, and performed a second genomic control on the 
meta-analysis level. For the 1KG imputed GWAS, we used METAL16 to perform a fixed effect meta-
analysis. We removed variants that were only available in <50% of the samples. The HapMap meta-
analysis included 2,437,193 variants, and the 1KG GWAS included 10,019,203 variants. We considered 
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associations with P<5×10-8 genome-wide significant. We used a stringent distance criterion, 500kb 
minimum between two significant variants, to identify distinct loci. In each locus, the variant with the 
smallest p-value was called the “lead variant”. Additionally, we performed sex-stratified analyses among 
HapMap imputed studies, and we tested for heterogeneity between sex-specific effect estimates as 
described previously17, using the false-discovery rate of Benjamini-Hochberg to assess significance of the 
P for sex difference (<0.05). We conducted BMI adjusted analyses in the 1KG meta-analysis to determine 
the role of BMI in mediating the genetic associations with CRP, and to increase power to detect 
associations not mediated by BMI.  
 
LD Score regression 
Because population stratification is a major concern in GWAS and may lead to false-positive associations, 
we applied Linkage Disequilibrium Score regression (LDSC) to distinguish whether the inflation of test 
statistics observed in the CRP GWAS is due to the polygenic architecture of CRP or reflects confounding 
bias due to cryptic relatedness or population stratification. The LD Score measures collective genetic 
variation acquired from all genetic variants in LD with the index tagging (causal) variant18. A higher LD 
score of an index variant implicates more nearby genetic variants in high LD with the index variant, which 
makes it more likely that the index variant tags causal variant(s). More genetic variants in LD with the 
index genetic variant (i.e., a higher LD score due to polygenicity) may yield higher (i.e., inflated) test 
statistics. In contrast, higher test statistics caused by cryptic population stratification will not be related to 
LD score. LD Score regression analysis performs regression of the summary statistics from the GWAS 
meta-analysis (χ2 statistics from the GWAS) on the LD scores across the genome. An intercept of the LD 
Score regression that equals one suggests no confounding bias, whereas an inflated intercept (larger than 
one) suggests contribution of confounding due to relatedness to the test statistics. We used the LDHub 
web interface to perform LD Score regression19. We filtered variants to the subset of HapMap 3 variants, 
and excluded variants with duplicated rs numbers, ambiguous variants, minor allele frequency 
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(MAF)<0.01, and reported sample size <66.7% of total sample size. We used the default European LD 
Score file based on the European 1KG reference panel. 
Furthermore, we applied cross-trait LD score regression to estimate genetic correlation of chronic 
inflammation (using the HapMap GWAS meta-analysis) with other phenotypes using published GWAS 
summary statistics20. In brief, the cross-product of two GWAS test statistics is calculated at each genetic 
variant, and this cross-product is regressed on the LD Score. The slope of the regression is used to 
estimate the genetic covariance between two phenotypes.  
 
Identification of additional distinct variants in associated loci 
To identify additional distinct variants in the associated loci, we performed joint approximate conditional 
analysis using the 1KG meta-analysis summary statistics and the linkage disequilibrium (LD) matrix 
derived from the first cohort of the Rotterdam study (RS-I) (n=5,974). We used the Genome-wide 
Complex Trait Analysis (GCTA) tool, which performs a genome-wide step-wise procedure to identify 
variants according to their distinct association with CRP (i.e., conditional P)21; 22. We only used variants 
with an imputation quality of R2>0.8 in the reference set (RS-I). This approximate conditional analysis 
may reveal different lead signals in a locus where multiple associated variants are in the final joint 
association model. We tested the distinct variants identified in the CRP gene jointly for an association 
with CRP using individual level data from the second and third cohort of the Rotterdam Study (RS-II and 
RS-III, totaling 5,024 subjects), and the Women’s Genome Health Study (WGHS) of 16,299 individuals. 
 
Proportion of CRP variance explained 
We estimated the variance explained in serum CRP levels using the formula (2*MAF(1-
MAF)beta2)/var(CRP), where beta is the estimated effect of the individual variants on CRP23 and 
var(CRP) is the variance in natural log-transformed CRP estimated in the RS-I cohort. We calculated the 
variance explained for four combinations of associated variants: 1. the lead variant at just the CRP locus; 
2. the distinct variants at the CRP locus derived from the 1KG joint conditional analysis; 3. all lead 
Page 16 of 35 
variants in the distinct loci; 4. all lead variants in the distinct loci and, when applicable, the distinct 
variants at associated loci derived from the approximate joint conditional analysis. 
 
Pathway analysis and gene expression 
We used Data-Driven Expression-Prioritized Integration for Complex Traits24 (DEPICT v.1 rel173 beta) 
to systematically prioritize the most likely causal genes, highlight the pathways that are enriched by the 
likely causal genes and identify tissues and cell types in which genes from associated loci are highly 
expressed. DEPICT requires summary statistics from the GWAS meta-analysis. First, we filtered genome-
wide associated variants from both GWAS meta-analyses by MAF>0.01, and selected variants with low 
correlation with other variants by PLINK (version 1.90) using a clumping distance of 500 kb apart and/or 
index of LD r2 threshold <0.1. The settings for the analysis involved the usage of 1KG pilot phase data25 
(phase 1 integrated release, version 3, CEU, GBR, TSI unrelated individuals; 2010.11.23) with r2>0.5 LD 
threshold for locus definition, 10,000 permutations for bias correction, and 500 repetitions for FDR 
calculation. To summarize and visualize the results, we calculated pairwise Pearson correlation 
coefficients between all gene-specific Z-scores for every pair of reconstituted DEPICT gene sets. We used 
Affinity Propagation Clustering (apcluster command; APCluster R package26) to identify clusters and 
representative examples of the clusters, and Cytoscape v3.2.1 for visualization of the results. The DEPICT 
results of the pathway and gene prioritization are summarized as a heatmap (R. v2.3.3, pheatmap v1.0.8 
package27). The gene-specific Z-score describes the likelihood that a given gene is part of the 
corresponding GO term, KEGG pathway, REACTOME pathway, Mouse Phenotype, or protein-protein 
interaction network.  
Also, we performed Multi-marker Analysis of GenoMic Annotation (MAGMA)28. MAGMA 
performs gene and gene-set analysis and requires the association results of all variants, therefore we chose 
the larger HapMap GWAS for MAGMA. We used the Functional Mapping and Annotation (FUMA)29 
tool to perform MAGMA, and applied standard settings for running MAGMA. 
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To prioritize the most likely trait-relevant gene for each GWAS locus, we run colocalization 
analysis using the “coloc” R package v3.130 separately for the HapMap and 1KG GWAS. We used 
publicly available genome-wide eQTL data from 5,311 whole blood samples31, and from the Genome 
Tissue Expression (GTEx) V6p portal incorporating eQTL data from 44 post-mortem tissues32. “Coloc” 
uses approximate Bayes factors to estimate the posterior probability that GWAS and eQTL effects share a 
single causal variant. All significant cis-eGenes or cis-eProbes (q<0.05 in GTEx; lowest cis-eQTL 
FDR<0.05 in Westra et al.31) were extracted ±1Mb from the lead SNP of each locus. The HapMap SNP 
positions were converted to hg19 with the liftOver command from the rtracklayer v1.38.3 package. We 
used the SNPs present in both the GWAS and eQTL datasets. For the HapMap GWAS, the 1KG GWAS 
and the GTEx eQTL datasets, we performed the test using association beta, standard error of beta, and 
minor allele frequency (MAF). For the data from Westra et al.31, we used association P-value, MAF, and 
sample size, and included only the subset of cis-eQTLs which are publicly available (up to significance 
FDR<0.5). We used default priors supplied by the coloc package (P1=1e-4, P2=1e-4, P12=1e-5; prior 
probabilities for association in GWAS, eQTL, and both datasets). Full MAF data were not available for 
the eQTL datasets, therefore we used the GIANT 1KG p1v3 EUR reference panel instead. We visualized 
the results as a heatmap using the pheatmap v1.0.8 R package.27.  
 
Mendelian randomization 
To assess the effect of CRP on complex disorders, we performed a two-sample Mendelian randomization 
(MR) study on nine clinical outcomes (Alzheimer’s disease (AD), bipolar disorder (BD), coronary artery 
disease (CAD), Crohn’s disease (CD), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), 
schizophrenia, and diastolic (DBP) and systolic blood pressure (SBP)) to which CRP showed a potentially 
causal association at a P<0.1 in a previous MR study13. We used the effect estimates of the 48 lead SNPs 
found to be associated with CRP in the HapMap GWAS, and the effect estimates of the four SNPs that 
were additionally found to be associated with CRP in the 1KG GWAS in a multiple instrument approach 
for the MR analyses (n=52 SNPs). Additionally, we separately studied the effect of rs2794520 at the CRP 
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locus to minimize the probability of horizontal pleiotropy that may be introduced in a multiple instrument 
approach. We tested the statistical significance of the association between the instrument and CRP using 
the formula:  
 
R2 is the variance explained of CRP by the genetic instrument (0.014 for the rs2794520 SNP and 0.065 for 
the 52-SNP score), n is the number of individuals included in the CRP GWAS, and k the number of 
variants included in the genetic score. The F statistic for the 52-SNP score was 273, and for the rs2794520 
SNP 2,902, indicating that both instruments were strong. 
For the clinical outcomes, we used summary statistics from the most recent meta-analysis of 
GWA studies. For diastolic and systolic blood pressure, we used data from the UK Biobank. The details of 
the outcome studies are summarized in Table S12. We implemented four different methods of MR 
analyses: Inverse-variance weighted method (IVW), MR-Egger, Weighted median (WM), and Penalized 
weighted median (PWM). We used the “TwoSampleMR” package in R for the MR analyses33. Further, we 
applied the Bonferroni method to correct for multiple testing (0.05/9 phenotypes = 5.6×10-3). When the Q-
statistic of the IVW analyses provided evidence for heterogeneity, the weighted median estimates were 
used for significance. The MR methods are described briefly below. 
Inverse-variance weighted (IVW): The causal estimate is obtained by regressing the SNP 
associations with the outcome on the SNP associations with the risk factor, with the intercept set to zero 
and weights being the inverse-variances of the SNP associations with the outcome. With a single genetic 
variant, the estimate is the ratio of coefficients betaY/betaX and the standard error is the first term of the 
delta method approximation betaYse/betaX. When all CRP-SNPs are valid IVs, the IVW estimates 
converge to the true causal effect. When one or more invalids IVs are present, (ie. one SNP has effect on 
outcome through a different pathway than CRP), the IVW estimate deviates from the true causal effect.  
MR-Egger: We used MR-Egger to account for potential unbalanced pleiotropy in the multiple 
variant instrument34. When unbalanced pleiotropy is present, an alternative effect (positive or negative) is 
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present between the SNP and the outcome that may bias the estimate of the causal association. The MR-
Egger method is similar to the IVW analysis, but does not force the intercept to pass through the origin. 
The slope of the MR-Egger regression provides the estimate of the causal association between CRP and 
the clinical outcome. An MR-Egger intercept that is significantly different from zero suggests directional 
pleiotropic effects that may bias uncorrected estimates of the causal effect. MR-Egger regression depends 
on the InSIDE (Instrument Strength Independent of Direct Effect) assumption, that states that the strengths 
of the effect of the SNP on the outcome is uncorrelated with the direct pleiotropic effect of the SNP on the 
outcome.  
Weighted median (WM) and penalized Weighted Median (PWM): We applied the median based 
method to provide robust estimates of causal association even in the presence of horizontal pleiotropy 
when up to 50% of the information contributed by the genetic variants is invalid35. In PWM analysis the 
effect of each variants is weighted by a factor that corresponds to the Q statistics (heterogeneity test) of 
the SNP; this means that most variants will not be affected by this correction, but the causal effect of the 
outlying variants, which are most likely to be invalid IVs, will be down-weighted.  
We displayed the individual SNP causal effect estimates and corresponding 95% confidence 
intervals in a forest plot. To assess whether one of the variants used in the genetic score had 
disproportionate effects, we performed “leave-one-out” analyses where one SNP at a time is removed 
from the score. We depicted the relationship between the SNP effect on CRP and the SNP effect on the 
clinical outcomes in a scatter plot, and plotted the individual SNP effect against the inverse of their 
standard error in a funnel plot. When unbalanced pleiotropy is absent, the causal effect estimates of the 
individual should center around the meta-analysis estimate in the funnel plot.   
We used the proportion of variance in CRP explained by the genetic instruments (0.014 for the 
rs2794520 SNP and 0.065 for the 52-SNP score) to perform power calculations for each outcome using 
the online tool mRnd36. We calculated the power to detect a relative 5%, 10%, 15%, and 20% difference in 
outcome risk. For example, a 10% difference refers to an OR of at least 0.90 or 1.10 in outcome risk 
(Table S13). 
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Results 
HapMap GWAS meta-analysis for CRP levels 
The HapMap meta-analysis identified 3,977 genome-wide significant variants at P<5×10-8 (QQ-plot 
Figure S1; Manhattan plot Figure S2), which mapped to 48 distinct loci (Table 1, Table S3). Of the 
previously reported 18 variants for CRP, 16 remained associated. Compared to the previous GWAS, the 
rs6901250 variant at the GPRC6A locus (P=0.09) and the rs4705952 variants at the IRF1 locus (P=2.7×10-
3) were not significant. The beta estimates for natural log-transformed CRP for each of the associated loci 
ranged from 0.020 to 0.229. We observed the strongest association for rs2794520 at the CRP gene 
(β=0.182 in the natural log-transformed CRP (mg/L) per copy increment in the coded allele, P=4.17×10-
523), followed by rs4420638 at the APOC1/E gene (β=0.229, P=1.23×10-305). Similarly to previous GWAS 
meta-analysis, the lead variant within the interleukin-6 receptor gene (IL6R) was rs4129267 (β=0.088, 
P=1.2×10-129). Related to the interleukin-6 pathway, we identified rs1880241 upstream of the IL6 gene (β= 
0.028, P=8.4×10-14). In addition to the previously described interleukin-1 signaling, the IL1RN-IL1F10 
locus (interleukin-1 receptor antagonist and interleukin-1 family member 10), we found rs9284725 within 
the interleukin-1 receptor 1 gene (IL1R1, β=0.02, P=7.3×10-11, Table 1). The sex-specific meta-analyses 
did not identify additional loci for CRP compared to the overall meta-analysis including both sexes. 
However, at four genetic variants we found evidence for heterogeneity in effect estimates between women 
and men (Table S4), though the directions of associations were consistent.  
 
1KG GWAS meta-analysis for CRP levels 
In the 1KG meta-analysis, 8,002 variants were associated with CRP at P<5×10-8 (QQ-plot Figure S3; 
Manhattan plot Figure S4). This resulted in 40 distinct loci, of which 36 overlapped with the HapMap 
meta-analysis (Table 1). The lead variant at the CRP locus in the 1KG GWAS was rs4287174 (β=-0.185, 
P=1.95×-398), which is in high LD with rs2794520 (r2=0.98), the lead variant at the CRP locus in the 
HapMap GWAS. Among eight of the overlapping loci, the lead variant was at the same position in both 
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GWAS (rs1260326, rs1490384, rs10832027, rs1582763, rs7310409, rs2239222, rs340005, and 
rs1800961). Compared with HapMap, the four additional variants identified in 1KG were rs75460349, 
rs1514895, rs112635299, and rs1189402. The variants rs1514895 and rs1189402 were available in the 
HapMap GWAS, but were not associated at the genome-wide threshold (respectively P=1.2×10-7 and 
P=8.1×10-3). The two variants rs75460349 and rs112635299 were not available in the HapMap GWAS, 
nor were variants in high LD (r2<0.8). The rs75460349 is a low frequency variant with a coded allele 
frequency of 0.97 (β=0.086, P=4.5×10-10). Also rs112635299 near the SERPINA1/2 gene is a low 
frequency variant with a MAF of 0.02 (β=0.107, P=2.1×10-10). Adjustment for BMI in the 1KG GWAS 
(n=147,827) revealed six additional loci that were not associated with CRP in the HapMap and 1KG 
primary analyses (Table 1; Table S5, QQ-plot Figure S5; Manhattan plot Figure S6). The associations at 
three lead variants were much reduced after adjustment for BMI (rs1558902 (FTO), Padjusted=0.40; 
rs12995480 (TMEM18), Padjusted=0.02; rs64343 (ABO), Padjusted =1.0×10-7). Both the FTO and TMEM18 
gene are well-known obesity genes. Except for the FTO, TMEM18, and ABO loci, all distinct loci 
identified in the primary 1KG analysis were also associated with CRP in the BMI adjusted 1KG analysis. 
No genome-wide significant association was observed on the X-chromosome in the 1KG GWAS 
including 102,086 individuals.  
 
LD score regression 
The HapMap GWAS LD Score regression intercept was 1.03 (standard error: 0.013), and the 1KG 
intercept was 1.02 (standard error 0.011). This suggests that a small proportion of the inflation is 
attributable to confounding bias (~12% for the HapMap GWAS and ~13% for the 1KG GWAS). Hence, 
the vast majority of inflation is due to the polygenic architecture of circulating CRP levels. As depicted in 
Figure 1, CRP showed strong positive genetic correlations with anthropometric traits (e.g., BMI: Rg=0.43, 
P=5.4×10-15), glycemic phenotypes (e.g., type 2 diabetes Rg=0.33, P=3.1×10-6), lipid phenotypes (e.g., 
triglycerides Rg=0.29, P=7.9×10-5), and coronary artery disease (Rg=0.23, P=2.4×10-5) (Table S6). By 
comparison, CRP showed inverse genetic correlations with educational attainment (e.g., college 
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completion Rg=-0.27, P=9.2×10-7), lung function (e.g., forced vital capacity Rg=-0.24, P=4.6×10-12), and 
HDL-cholesterol (Rg=-0.30, P=4.8×10-9). 
 
Additional signals at distinct loci 
Approximate conditional analyses in the 1KG GWAS revealed additional signals at nine loci (Table S7). 
Five loci showed one secondary signal (IL6R, NLRP3, HNF1A, CD300LF, and APOE/APOC1), the 
PPP1R3B locus had two additional signals, the LEPR locus had three additional signals, and the SALL1 
locus had four additional signals, whereas the CRP locus showed a total of 13 distinct associated variants. 
Interestingly, the rs149520992 rare variant (MAF=0.01) mapping to the CRP locus showed an association 
at Pconditional=3.7×10-15 with β=-0.272 for the T-allele. The GCTA effect estimates for the ten distinct 
variants in the vicinity of the CRP gene identified in the 1KG conditional analysis are in high correlation 
with the effect estimates of these variants obtained from the RS-I and WGHS individual level data 
(rRS=0.97, and rWGHS=0.84), confirming the reliability of the GCTA estimates.  
 
Variance explained of CRP 
The lead variant at the CRP locus in both the HapMap (rs2794520) and 1KG (rs4287174) GWAS 
explained 1.4% of the variance in natural log-transformed CRP levels. The distinct variants at the CRP 
locus derived from the joint conditional analysis in the 1KG GWAS explained 4.3% of the variance. The 
lead variants at all distinct loci together explained 6.2% of the CRP variance in the HapMap GWAS, and 
6.5% in the 1KG GWAS. When we added the distinct variants at associated loci derived from the 
conditional analysis, the variance explained by all associated loci was 11.0% in the 1KG GWAS. 
 
Functional annotation 
We applied DEPICT and MAGMA analyses for functional annotation and biological interpretation of the 
findings. The DEPICT analysis included 9,497 genome-wide significant variants, covering 283 genes, and 
prioritized 55 candidate genes across 29 regions (FDR<0.05, Table S8). The prioritized genes included 
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IL6R mapping to the 1q21.3 locus (represented by rs4129267) and APCS to the 1q32.2 locus. 
Investigating 10,968 reconstituted gene sets for enrichment, DEPICT highlighted 583 (5.3%) gene sets to 
be significantly enriched among CRP-associated loci at FDR<0.05 (Table S9). Using further clustering, 
we identified 66 groups of gene sets that substantially correlated and clustered in two sets, one mainly 
comprised of immune pathways, and the other enriched for metabolic pathways (Figure 2). In Figure 3, we 
present the prioritized genes and the most significant gene sets. We found synovial fluid, liver tissue, and 
monocytes to be enriched for the expression of the prioritized genes (FDR<0.05). The MAGMA analysis 
was applied on the HapMap GWAS, identifying five significantly enriched gene sets (Bonferroni-
corrected P<0.05, Table S10). Results included consequences of gene EGF induction, positive regulation 
of gene expression, and IL-6 signaling pathway, in line with the most strongly prioritized gene from 
DEPICT gene prioritization. MAGMA analysis prioritized liver as a sole enriched tissue (P=0.048). 
To prioritize the most likely trait-relevant gene for each GWAS locus, we interrogated the GWAS 
data with cis-eQTL data identified from 44 post-mortem tissues and a large whole blood eQTL meta-
analysis using colocalization analysis (Table S11). Figure S7 presents the GWAS loci that colocalize with 
cis-eQTLs with the corresponding tissue, the colocalizing gene, and the posterior probability of one shared 
underlying variant driving both associations. Out of the 58 lead gSNPs, 25 SNPs (43%) showed evidence 
of colocalization with one or more local eQTL effects (posterior probability >0.9). For example, the 
rs2293476 locus colocalizes with several cis-eQTL effects for PABC4, and pseudogenes OXCT2P1, 
RP11−69E11.4, and RP11−69E11.8. The rs10925027 locus shows colocalization with cis-eQTL effect 
for NLRP3, exclusively in the highly powered blood meta-analysis. Out of 25 loci, for nine loci there was 
only one colocalizing gene. Altogether, gSNP-associated cis-eQTL effects were present in up to 14 
different tissues, with whole blood, esophagus mucosa, skin, and tibial nerve being the most frequent. 
 
Mendelian randomization analyses 
We observed a protective effect of genetically determined variance in CRP with schizophrenia with an 
IVW odds ratio (OR) of the 52-SNP score of 0.89 (95%CI: 0.81-0.97, P=6.6×10-3) (Tables S14-S15, 
Page 24 of 35 
Figure S8-S11). The MR-Egger intercept was compatible with no unbalanced pleiotropy (P=0.48). The 
estimate of the rs2794520 variant was comparable to the 52-SNP score estimate (OR 0.89, 95% CI 0.84-
0.94, P=0.046). The WM and PWM estimates were comparable to the IVW estimate (ORWM 0.89, 
PWM=5.1×10-3; ORPWM 0.89, PPWM=4.4×10-3). The “leave-one-out” analysis provided evidence that no 
single variant was driving the IVW point estimate (Figure S10). The causal OR between the rs2794520 
variant and BD was 1.33 (95% CI 1.03-1.73, P=0.032). For the 52-SNP score, the IVW OR was 1.16 
(95% CI 1.00-1.35, P=0.054). The MR-Egger intercept was compatible with unbalanced pleiotropy 
(P=0.049). The MR-Egger estimate OR of the 52-SNP score was comparable to the rs2794520 estimate 
(OR 1.36, 95%CI 1.1.-1.69, P=6.7×10-3), as were the WM and PWM estimates (ORWM 1.33, PWM=3.4×10-
3; ORPWM 1.32, PPWM=4.3×10-3). 
 We observed evidence against a causal association between either CRP rs2794520 (OR 1.01, 
95%CI 0.91-1.12, P=0.88), or the 52-SNP instrument (OR 0.96, 95%CI 0.84-1.09, P=0.51) and CAD. An 
Egger intercept of 0.014 suggested presence of unbalanced pleiotropy (P=5.8×10-3), with an MR-Egger 
causal estimate of OR 0.79 (95%CI 0.67-0.94, P=0.012). However, the WM and PWM showed no 
association between CRP and CAD. For AD, there was evidence against an association with rs2794520 
(P=0.592), though the IVW OR showed a protective effect (OR 0.51, 95%CI 0.30-0.88, P=0.015). The 
Egger intercept of 0.046 suggested unbalanced pleiotropy (P=0.042), and the MR-Egger OR was 0.27 
(95%CI 0.12-0.60). However, the association was null for the WM and PWM analyses (ORWM 1.04, 
PWM=0.61; ORPWM 1.05, PPWM=0.53). We observed evidence against an effect for CD, DBP, IBD, RA, and 
SBP for the rs2794520 variant and the IVW, MR-Egger, WM, and PWM analyses. 
 
Discussion 
Using genomic data from >200,000 individuals, we have identified 58 distinct signals for circulating CRP 
levels, confirming 16 previously identified CRP loci. BMI-adjusted GWAS suggested that the vast 
majority of genetic risk variants affect CRP levels independent of its main determinant (BMI). The 
genome-wide in silico functional annotation analysis highlights 55 genes which are likely to explain the 
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association of 29 signals to CRP levels. The data identified gene sets involved in the biology of immune 
system and liver as main regulators of serum CRP levels. Mendelian randomization analyses supported 
causal associations of genetically increased CRP with a protective effect on schizophrenia, and increased 
risk of bipolar disorder.  
Obesity is one of the main determinants of chronic low-grade inflammation in the general 
population37; 38. Adjustment for BMI in the CRP GWAS abolished the association at only three lead 
variants, suggesting that the genetic regulation of chronic low-grade inflammation is largely independent 
from BMI. Notably, BMI adjustment resulted in the identification of six variants that were not associated 
with CRP in the BMI-unadjusted GWAS. This supports the notion that adjustment for covariates that 
explain phenotypic variance may improve the statistical power in linear model analyses of quantitative 
traits39. Although adjustment for heritable correlated traits in GWAS may bias effect estimates (collider 
bias)40, there is consistent evidence in the literature that BMI has a causal direct effect on CRP levels41, 
and therefore, collider bias in CRP GWAS adjusted for BMI is less likely.  
The sex-stratified analyses revealed significant heterogeneity in effect estimates between men and 
women at only four lead variants, which represent less than 10% of all CRP loci. Even among these four 
loci the effect directions were similar, thus the heterogeneity was limited to effect sizes. The data suggest 
that the difference between men and women in CRP levels is less likely to be explained by genetic factors. 
Furthermore, two signals identified in the former HapMap GWAS of CRP levels were not significant in 
the current HapMap GWAS. The effect estimates in the current analyses were too small to identify with 
our sample size. 
The top variant at the CRP locus in both the HapMap and 1KG GWAS explained 1.4% of the 
variance in circulating CRP levels. The approximate conditional analysis resulted in 13 variants jointly 
associated within the CRP locus in the 1KG GWAS. With respect to locus definition, we used a 
conservative distance criterion compared to other GWA studies that often use ±500kb surrounding the 
GWAS peak42. Here, we used the criterion that the minimum distance between the boundaries of loci is 
500kb. In order to identify further variants associated with CRP levels, we performed approximate 
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conditional analyses resulting in multiple putative additional variants, also inside and near genes that were 
not identified in the primary GWAS. As an example, the CRP locus spanned >2MB according to our 
criterion. Approximate conditional analysis revealed that two variants, namely rs3027012 near DARC and 
rs56288844 near FCER1A, both downstream of the CRP gene, were associated with CRP levels. 
Furthermore, upstream of CRP, we identified a variant near FCGR2A (Immunoglobulin G Fc Receptor II). 
These results show that for a given lead variant, potentially multiple causal loci, here DARC, FCER1A, 
and FCGRA2, alongside CRP contribute to chronic low-grade inflammation and variation in circulating 
CRP levels. 
DEPICT analysis provided further evidence that the genes annotated to the associated CRP 
variants mainly cluster in the immune and liver biological systems. Notably, the gene set “inflammatory 
response”, which captures both immune response and liver metabolism, was the main connector network 
between the two networks. This is in line with the observation that CRP is mainly produced by liver cells 
in response to inflammatory cytokines during acute and chronic inflammation43. Interestingly, the analysis 
highlighted iron homeostasis as an enriched gene set. In agreement, the conditional analysis highlighted a 
distinct genetic association at the hemochromatosis gene HFE, a transmembrane protein of the major 
histocompatibility complex (MHC) class I family. Previous studies show that iron metabolism plays a 
pivotal role in inflammation44; 45. However, genetic pleiotropy may highlight co-regulated networks in 
pathway analysis that are not causal to inflammation per se. It is also important to note that the results of 
DEPICT analyses apply to reconstituted gene sets which may sometimes have slightly different overlaying 
biological theme than the original gene set annotation. 
The MR analyses validate previous evidence that genetically-elevated CRP is protective for the 
risk of schizophrenia13; 46, although observational data suggest a positive association between CRP and 
risk of schizophrenia47. For bipolar disorder we observed a positive causal effect, which is in line with 
previous MR and observational studies13; 48. Although the causal underlying mechanisms remain to be 
elucidated, a hypothesis for the schizophrenia observation might be the immune response to infections 
early in life. Levels of acute-phase response proteins in dry blood spots collected at birth are lower for 
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patients with non-affective psychosis, which includes schizophrenia, compared to controls, suggesting a 
weaker immune response at birth49. Also, neonates that have been exposed to a maternal infection and 
have low levels of acute-phase response proteins, have a higher risk of schizophrenia50. Altogether, the 
evidence suggests that a deficient immune response may contribute to chronic infection in children and the 
development of schizophrenia. For AD and CAD, the Egger intercept showed evidence of unbalanced 
pleiotropy and the Egger estimate showed a protective effect of CRP on the risk of AD and CAD. 
However, for both outcomes, the effects of the WM and PWM analyses, as well as analyses using the 
single rs2794520 variant (which is least likely to be affected by pleiotropy) were null. The MR-Egger 
estimate relies on the InSIDE assumption which states that the strength of the association between the 
genetic variants and CRP is independent from the strength of the direct pleiotropic effects of the genetic 
variants on the outcome. This assumption may be violated when the genetic variants are associated with a 
confounder of the CRP-outcome association. Such a scenario may occur when the genetic variants are 
associated with an exposure that is causally upstream of the exposure under study. In the context of the 
association of CRP with AD and CAD, this could be lipids or glycemic phenotypes. Several genetic 
variants used in the 52-SNP instrument are associated with metabolic phenotypes that may affect CRP 
levels. In agreement, the WM and PWM, in which the InSIDE assumption is relaxed, and the single 
variant analysis showed no association. Furthermore, the observation that CRP is not causally related to 
CAD in the MR analyses is in comparison to previous published studies51. Power calculation showed that 
we had 100% power to detect a 10% difference in CAD risk, thus the probability of a false negative 
finding is small. Also, CRP is associated with future CAD in observational studies, and randomized trials 
have shown a beneficial effect of lowering inflammation using statins52 and canakinumab53 on CAD risk, 
but this effect is unlikely to be attributable to CRP. 
The strengths of our study are the use of a very large sample size for CRP and the use of both 
HapMap and 1KG imputed data. Furthermore, we conducted sex-specific and BMI-adjusted analyses to 
study the effect of sex and body mass on the associations between genetic variants and CRP. To maximize 
power and to efficiently use the data, we meta-analyzed all available samples in a discovery setting 
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without replication. The consistent association of the variants in >50 studies at a strict Bonferroni 
corrected threshold provide confidence that our findings represent true associations. We used both 
HapMap and 1KG imputed data to identify genetic variants for circulating CRP levels. At the start of the 
project, more studies had HapMap imputed data available. Hence, the sample size and thus power in the 
HapMap GWAS was higher compared to the 1KG. Also, HapMap may identify variants that are not 
identified in 1KG GWAS54. Nevertheless, 1KG offers better coverage of uncommon variants and includes 
INDELs, which are not included in the HapMap reference panel. Including both reference panels, we used 
all available samples and maximized the possibility to identify genetic variants for CRP, both common 
and uncommon.  
However, we note limitations to our study. GWAS merely identify loci associated with complex 
phenotypes and the identification of causal genes remains challenging. We only included individuals of 
European ancestry; the generalizability of our findings to other races/ethnicities is uncertain. In addition, 
although our analyses provided support for causal associations, we acknowledge that we may not have 
identified the causal variants and we may not have eliminated residual confounding. The colocalisation 
analyses provide evidence for colocalisation of CRP GWAS signals and eQTLs, however, it does not 
provide evidence that the GWAS signal is functioning on CRP through the gene expression. We further 
note that the method assumes identical LD-structure from the GWAS and eQTL datasets. As there are 
~14% of non-European samples in the full GTEx dataset, this assumption might be violated for some 
tissues. Last, we meta-analyzed all available samples in one meta-analysis and did not replicate our 
findings in an independent sample. Therefore, our findings may need replication. 
In conclusion, we performed a large GWAS meta-analysis to identify genetic loci associated with 
circulating CRP levels, a sensitive marker of chronic low-grade inflammation, and found support for a 
causal role of CRP with a decreased risk of schizophrenia and higher risk of bipolar disorder. As 
inflammation is implicated in the pathogenesis of multiple complex diseases, the new insights into the 
biology of inflammation obtained in the current study may contribute to future therapies and interventions. 
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Figure Legends 
Figure 1. Genome-wide genetic correlation between serum CRP levels and different phenotypes and 
clinical diseases. The genetic correlation and its standard error are estimated with linkage disequilibrium 
score regression analysis. ADHD, attention deficit and hyperactivity disorder; FEV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; HOMA-B, homeostatic model assessment β-cell function; 
HOMA-IR, homeostatic model assessment insulin resistance; HbA1C, Hemoglobin A1c.  
 
Figure 2. Results of the DEPICT functional annotation analysis. Each node represents exemplar gene 
set from Affinity Propagation clustering and links represent corresponding Pearson correlation coefficients 
between individual enriched gene sets (only the links with r>0.3 are shown). As an example, outlined are 
the individual gene sets inside two clusters (“Inflammatory response” and “negative regulation of 
peptidase activity”). 
 
Figure 3. Heatmap representing the results of DEPICT functional annotation analysis. Each row 
represents enriched (FDR < 0.05) gene sets and each column represents prioritized (FDR<0.05) genes. 
Colors on the heatmap represent each gene´s contribution to gene set enrichment (depicted as Z-score, 
only top 10 highest Z-scores per gene set are visualized). Sidebars represent p-values for GWAS, gene set 
enrichment (GSE), and gene prioritization (nominal P-value on log10 scale). Top 10 gene sets per 
annotation category are visualized. GO, Gene Ontology; KE, Kyoto Encyclopedia of Gene and Genomes; 
RE, REACTOME pathways; MP, Mouse Phenotypes; PI, protein-protein interactions.  
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Table 1. Newly identified loci associated with C-reactive protein. 1 
Variant Chr Position Coded allele Coded allele freq Beta SE P-value Closest gene 1KG lead variant 
Loci found in the HapMap GWAS       
rs469772 1 91530305 T 0.19 -0.031 0.005 5.54×10-12 ZNF644 rs469882 
rs12995480 2 629881 T 0.17 -0.031 0.005 1.24×10-10 TMEM18 rs62105327 
rs4246598 2 88438050 A 0.46 0.022 0.004 5.11×10-10 FABP1 - 
rs9284725 2 102744854 C 0.24 0.027 0.004 7.34×10-11 IL1R1 rs1115282 
rs1441169 2 214033530 G 0.53 -0.025 0.004 2.27×10-11 IKZF2 - 
rs2352975 3 49891885 C 0.30 0.025 0.004 6.43×10-10 TRAIP rs10049413 
rs17658229 5 172191052 C 0.05 0.056 0.010 5.50×10-09 DUSP1 rs34471628 
rs9271608 6 32591588 G 0.22 0.042 0.005 2.33×10-17 HLA-DQA1 rs2647062 
rs12202641 6 116314634 T 0.39 -0.023 0.004 3.00×10-10 FRK - 
rs1490384 6 126851160 T 0.51 -0.025 0.004 2.65×10-12 C6orf173 rs1490384 
rs9385532 6 130371227 T 0.33 -0.026 0.004 1.90×10-11 L3MBTL3 - 
rs1880241 7 22759469 G 0.48 -0.028 0.004 8.41×10-14 IL6 rs13241897 
rs2710804 7 36084529 C 0.37 0.021 0.004 1.30×10-08 KIAA1706 - 
rs2064009 8 117007850 C 0.42 -0.027 0.004 2.28×10-14 TRPS1 rs6987444 
rs2891677 8 126344208 C 0.46 -0.020 0.004 1.59×10-08 NSMCE2 rs10956251 
rs643434 9 136142355 A 0.37 0.023 0.004 1.02×10-09 ABO 9:136146061 
rs1051338 10 91007360 G 0.31 0.024 0.004 2.27×10-09 LIPA - 
rs10832027 11 13357183 G 0.33 -0.026 0.004 4.43×10-12 ARNTL rs10832027 
rs10838687 11 47312892 G 0.22 -0.031 0.004 9.12×10-13 MADD rs7125468 
rs1582763 11 60021948 A 0.37 -0.022 0.004 2.37×10-09 MS4A4A rs1582763 
rs7121935 11 72496148 A 0.38 -0.022 0.004 5.28×10-09 STARD10 - 
rs11108056 12 95855385 G 0.42 -0.028 0.004 5.42×10-14 METAP2 rs12813389 
rs2239222 14 73011885 G 0.36 0.035 0.004 9.87×10-20 RGS6 rs2239222 
rs4774590 15 51745277 A 0.35 -0.022 0.004 2.71×10-08 DMXL2 rs1189402 
rs1558902 16 53803574 A 0.41 0.034 0.004 5.20×10-20 FTO rs55872725 
rs178810 17 16097430 T 0.56 0.020 0.004 2.95×10-08 NCOR1 - 
rs10512597 17 72699833 T 0.18 -0.037 0.005 4.44×10-14 CD300LF,RAB37 rs2384955 
rs4092465 18 55080437 A 0.35 -0.027 0.004 3.11×10-10 ONECUT2 - 
rs12960928 18 57897803 C 0.27 0.024 0.004 1.91×10-09 MC4R - 
rs2315008 20 62343956 T 0.31 -0.023 0.004 5.36×10-10 ZGPAT - 
rs2836878 21 40465534 G 0.27 0.043 0.004 7.71×10-26 DSCR2 rs4817984 
rs6001193 22 39074737 G 0.35 -0.028 0.004 6.53×10-14 TOMM22 rs4821816 
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Additional loci found in the 1KG GWAS       
rs75460349 1 27180088 A 0.97 0.086 0.014 4.50×10-10 ZDHHC18  
rs1514895 3 170705693 A 0.71 -0.027 0.004 2.70×10-09 EIF5A2  
rs112635299 14 94838142 T 0.02 -0.107 0.017 2.10×10-10 SERPINA1/2  
rs1189402 15 53728154 A 0.62 0.025 0.004 3.90×10-09 ONECUT1  
        
Additional loci found in the BMI adjusted 1KG GWAS     
3:47431869 3 47431869 D 0.59 0.024 0.004 1.10×10-08 PTPN23  
rs687339 3 135932359 T 0.78 -0.030 0.005 2.80×10-10 MSL2  
rs7795281 7 74122854 A 0.76 0.028 0.005 3.10×10-08 GTF2I  
rs1736060 8 11664738 T 0.60 0.029 0.004 2.60×10-13 FDFT1  
17:58001690 17 58001690 D 0.44 -0.026 0.004 9.50×10-10 RPS6KB1  
rs9611441 22 41339367 C 0.49 -0.022 0.004 1.40×10-08 XPNPEP3  
β coefficient represents 1-unit change in the natural log-transformed CRP (mg/L) per copy increment in the allele A1. Freq is the frequency of A1. Position is 2 
according to Hg19. When a variant is located within a gene, that gene is reported in the closest gene column, otherwise the closest gene. The HapMap variants 3 
are presented, except for the 1KG additional findings. For the HapMap loci, the lead variant from the 1KG GWAS is presented when the locus was also found in 4 
the 1KG GWAS. 5 
